Working to Eradicate Gynecologic Cancers

Scientific Plenary IX: Multimodal Therapy and Predictors of Response

Tuesday, March 25, 2014: 10:25 AM-11:50 AM
Ballroom B/C (Tampa Convention Center)
Description:
Moderator:  Anuja Jhingran, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
10:25 AM
Moderator Introductions
A. Jhingran
The University of Texas MD Anderson Cancer Center, Houston, TX
 

 
10:31 AM
140 - Scientific Plenary
Concurrent chemoradiation with paclitaxel in high-risk endometrial cancer patients after surgery: a Korean Gynecologic Oncology Group study
S. M. Hwang, H. Cho, D. B. Chay, S. Kim and J. H. Kim
Yonsei University College of Medicine, Seoul, South Korea
 

 
10:42 AM
141 - Scientific Plenary
Multimodal therapy improves progression-free survival in patients with stage I-III uterine carcinosarcoma: a multi-institutional study
E. L. Dickson1, R. Isaksson Vogel1, P. A. Gehrig2, S. R. Pierce2, L. J. Havrilesky3, A. A. Secord3, J. A. Dottino3, A. Nickles Fader4, S. Ricci4 and M. A. Geller1
1University of Minnesota, Minneapolis, MN, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Johns Hopkins Medical Institutions, Baltimore, MD
 

 
10:53 AM
Debate (Pro): The importance of the addition of pelvic radiation treatment in the treatment of high-risk endometrial carcinoma, including carcinosarcoma
A. Jhingran
The University of Texas MD Anderson Cancer Center, Houston, TX
 

 
11:01 AM
Debate (Con): Chemotherapy is enough in the treatment of high-risk endometrial carcinoma, including carcinosarcoma
S. A. Davidson
University of Colorado School of Medicine, Aurora, CO
 

 
11:09 AM
142 - Scientific Plenary
A cost-effectiveness analysis of four chemotherapy regimens used in the treatment of platinum-sensitive recurrent epithelial ovarian carcinoma
E. D. Schroeder1, J. De La Garza1, A. E. Garcia-Soto2, K. E. Hew1, J. M. Pearson3, F. Simpkins4, J. A. Lucci III5, J. P. Diaz6, F. Andrade1 and X. Burbano-Levy7
1University of Miami-Jackson Memorial Hospital, Miami, FL, 2University of Miami Jackson Memorial Hospital, Miami, FL, 3University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, 4University of Miami, Miami, FL, 5University of Miami Miller School of Medicine, Miami, FL, 6South Miami Gynecologic Oncology Group, Miami, FL, 7Zilonis Health, Inc., Miami, FL
 

 
11:20 AM
143 - Scientific Plenary
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study
K. S. Tewari1, M. Sill2, B. J. Monk3, H. J. Long4, R. T. Penson5, H. Huang2, L. M. Landrum6, A. Oaknin7, H. Michael8, D. H. Moore9, M. M. Leitao10, L. M. Ramondetta11 and T. J. Reid12
1University of California at Irvine, Irvine, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4Mayo Clinic, Rochester, MN, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6The University of Oklahoma, Oklahoma City, OK, 7GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 8Indiana University School of Medicine, Indianapolis, IN, 9Franciscan Physician Network Gynecologic Oncology Specialists, Indianapolis, IN, 10Memorial Sloan Kettering Cancer Center, New York, NY, 11The University of Texas MD Anderson Cancer Center, Houston, TX, 12University of Cincinnati, Cincinnati, OH
 

 
11:29 AM
144 - Scientific Plenary
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study
K. S. Tewari1, M. Sill2, D. H. Moore3, H. J. Long4, R. T. Penson5, H. Huang2, L. M. Landrum6, A. Oaknin7, H. Michael8, B. J. Monk9, L. M. Ramondetta10, T. J. Reid11 and M. M. Leitao12
1University of California at Irvine, Irvine, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Franciscan Physician Network Gynecologic Oncology Specialists, Indianapolis, IN, 4Mayo Clinic, Rochester, MN, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6The University of Oklahoma, Oklahoma City, OK, 7GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 8Indiana University School of Medicine, Indianapolis, IN, 9University of Arizona Cancer Center, Phoenix, AZ, 10The University of Texas MD Anderson Cancer Center, Houston, TX, 11University of Cincinnati, Cincinnati, OH, 12Memorial Sloan Kettering Cancer Center, New York, NY
 

 
11:37 AM
145 - Scientific Plenary
A comparative analysis of the treatment strategies for advanced ovarian cancer
J. M. Scalici, D. DeCotis-Smith, B. Wang, M. A. Finan and R. P. Rocconi
University of South Alabama, Mobile, AL
 
11:47 AM
Questions & Floor Discussion
 
See more of: Scientific Plenary
<< Previous Course | Next Course >>